Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers.
A live-attenuated dengue 2 vaccine (strain 16681 PDK 53) developed at Mahidol University, Thailand was evaluated for safety and immunogenicity by administering 10(4) p.f.u. subcutaneously to ten flavivirus non-immune American volunteers. The vaccine was safe; there were no serious adverse reactions. Eight recipients experienced no or mild side effects. One recipient reported headaches on 7 separate days. One volunteer, who had a fracture of the humerus 1 day after vaccination requiring surgical repair, experienced generalized malaise with fever (maximum temperature = 38.9 degrees C), headache, eye pain and myalgia lasting less than 24 h. The vaccine was highly immunogenic; all recipients developed neutralizing antibody that persisted for two years.
Vaughn
D W
DW
Armed Forces Research Institute of Medical Sciences, APO AP 96546, USA.
Hoke
C H
CH
Yoksan
S
S
LaChance
R
R
Innis
B L
BL
Rice
R M
RM
Bhamarapravati
N
N
D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000096:biosynthesis; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D003716:Dengue Virus / Q000276:immunology* / Q000502:physiology; D005260:Female; D006801:Humans; D007075:Immunoglobulin M / Q000096:biosynthesis; D008213:Lymphocyte Activation / Q000187:drug effects / Q000276:immunology; D008297:Male; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D014613:Vaccines, Attenuated / Q000009:adverse effects / Q000276:immunology / Q000494:pharmacology; D014765:Viral Vaccines / Q000276:immunology* / Q000494:pharmacology*; D014779:Virus Replication / Q000187:drug effects
D000914:Antibodies, Viral; D007075:Immunoglobulin M; D014613:Vaccines, Attenuated; D014765:Viral Vaccines